Parkinson DiseaseLuxPARKNCT05266872
Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme
An observational study of Parkinson Disease, run by Luxembourg Institute of Health at 2 sites in Luxembourg.
Trial summary
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- Observational study with sample and data collection
- How many people
- 1,800 participants
- Where
- 2 sitesLuxembourg
- Study dates
- 19 Dec 2014to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.
Who may be able to join
- Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
- Subjects of all genders with a full capacity of consent
- Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
- Subjects of at least 18 years of age at the time of inclusion
Who cannot join
- Refusal to sign the informed consent
- Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
- Active cancer
- Pregnant women
- Underage subjects of less than 18 years of age
- Refusal to comply with mandatory sample collection
- For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Luxembourg2 sites, 2 recruiting
- Recruiting
Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic"
Luxembourg, 1210
Rejko KRÜGER, +35244114848, rejko.krueger@uni.lu
- Recruiting
Clinical and Epidemiological Investigation Center (CIEC)
Luxembourg, 1445
Manon Gantenbein, +352 26970-807, Manon.Gantenbein@lih.lu
About this study
Official title: Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
- Conditions
- Parkinson Disease
- Being tested
- Observational study with sample and data collection
- Keywords
- Parkinson's disease, longitudinal cohort, stratification, risk factors
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational study with sample and data collectionOther
Observational study with sample and data collection
| Study group | Role | What they receive |
|---|---|---|
| PD patients | Subjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) Receives: Other: Observational study with sample and data collection | |
| Healthy controls | Gender- and age-matched healthy controls Receives: Other: Observational study with sample and data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls
1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.
Measured: through study completion, an average of 8 years
2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.
2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.
Measured: through study completion, an average of 8 years
Determine Parkinson's disease biomarker signatures
3.1. Identify new and early diagnostic biomarkers
Measured: through study completion, an average of 8 years
Develop a mechanistic understanding of the disease
4.1. Understand the mechanisms of PD pathogenesis.
Measured: through study completion, an average of 8 years
Secondary outcomes (2)
Inform future studies testing new therapies for Parkinson's disease
1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.
Measured: through study completion, an average of 8 years
Harmonization of data with international Parkinson's disease cohort studies
2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.
Measured: through study completion, an average of 8 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2022
- Study start19 Dec 2014
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Luxembourg Institute of Health
- Sponsor type
- Other government
- Collaborators
- University of Luxembourg, Laboratoire National de Santé (LNS), Centre Hospitalier du Luxembourg
- Responsible party
- Sponsor
- Investigators
- Rejko Rejko, Dr, Principal investigator, Luxembourg Institute of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05266872
- Sponsor's protocol ID
- CNER 140174_ND
- Acronym
- LuxPARK
- Status last verified
- Sep 2026
- First submitted
- 17 Jun 2021
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pavelka L, Rawal R, Ghosh S, Pauly C, Pauly L, Hanff AM, Kolber PL, Jonsdottir SR, Mcintyre D, Azaiz K, Thiry E, Vilasboas L, Soboleva E, Giraitis M, Tsurkalenko O, Sapienza S, Diederich N, Klucken J, Glaab E, Aguayo GA, Jubal ER, Perquin M, Vaillant M, May P, Gantenbein M, Satagopam VP, Kruger R; NCER-PD Consortium. Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism. Front Neurol. 2023 Dec 19;14:1330321. doi: 10.3389/fneur.2023.1330321. eCollection 2023.
PubMed 38174101
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)
- ClinicalTrials.gov ID
- NCT05266872
- Acronym / sponsor ID
- LuxPARK / CNER 140174_ND
- Conditions
- Parkinson Disease
- Keywords
- Parkinson's disease, longitudinal cohort, stratification, risk factors
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,800 participants (estimated)
- Lead sponsor
- Luxembourg Institute of HealthOther government
- Collaborators
- University of Luxembourg, Laboratoire National de Santé (LNS), Centre Hospitalier du Luxembourg
- Study start
- 19 Dec 2014 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 4 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PD patients | – | Other: Observational study with sample and data collectionSubjects with neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) |
| Healthy controls | – | Other: Observational study with sample and data collectionGender- and age-matched healthy controls |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects with a neurodegenerative disease or having degenerative parkinsonism (typical PD or atypical parkinsonism) and gender- and age-matched healthy controls.
Key inclusion criteria (4 listed)
- Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)
- Subjects of all genders with a full capacity of consent
- Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement
- Subjects of at least 18 years of age at the time of inclusion
Key exclusion criteria (7 listed)
- Refusal to sign the informed consent
- Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion
- Active cancer
- Pregnant women
- Underage subjects of less than 18 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational study with sample and data collectionObservational study with sample and data collection | Other | Healthy controls, PD patients |
Primary outcome
1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls
Time frame: through study completion, an average of 8 years
1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.
2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.
Time frame: through study completion, an average of 8 years
2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.
Determine Parkinson's disease biomarker signatures
Time frame: through study completion, an average of 8 years
3.1. Identify new and early diagnostic biomarkers
Develop a mechanistic understanding of the disease
Time frame: through study completion, an average of 8 years
4.1. Understand the mechanisms of PD pathogenesis.
2 secondary outcomes
Inform future studies testing new therapies for Parkinson's disease
Time frame: through study completion, an average of 8 years
Harmonization of data with international Parkinson's disease cohort studies
Time frame: through study completion, an average of 8 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Derived from this study: PubMed 38174101Pavelka L, Rawal R, Ghosh S, Pauly C, Pauly L, Hanff AM, Kolber PL, Jonsdottir SR, Mcintyre D, Azaiz K, Thiry E, Vilasboas L, Soboleva E, Giraitis M, Tsurkalenko O, Sapienza S, Diederich N, Klucken J, Glaab E, Aguayo GA, Jubal ER, Perquin M, Vaillant M, May P, Gantenbein M, Satagopam VP, Kruger R; NCER-PD Consortium. Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism. Front Neurol. 2023 Dec 19;14:1330321. doi: 10.3389/fneur.2023.1330321. eCollection 2023.
- Website accessible by participants and researcher giving information on the study an related activitiesLink provided by the sponsor.
- Publication on the initial cohortLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rejko Rejko, Dr principal investigator
Luxembourg Institute of Health
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by Luxembourg Institute of Health at 2 sites in Luxembourg.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Luxembourg. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rejko KRÜGER, Dr (+352 44 11 4848, rejko.krueger@uni.lu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls (time frame: through study completion, an average of 8 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05266872, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.